deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT01876433

Beta 3 Agonist Treatment in Heart Failure (Beat-HF)

Sponsor: Henning Bundgaard

Conditions Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions Mirabegron Placebo
Updated 7 times since 2017 Last updated: Oct 14, 2020 Started: Sep 30, 2013 Primary completion: Sep 30, 2015 Completion: Sep 30, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01876433, this PHASE2 trial focuses on Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) and remains completed. Sponsored by Henning Bundgaard, it has been updated 7 times since 2013, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Jul 2017 · 6 months · monthly snapshotRecruiting~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotUnknown Status~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshotUnknown Status~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Unknown Status → Completed

  5. Jun 2018 — Nov 2020 [monthly]

    Unknown Status PHASE2

▶ Show 2 earlier versions

  1. Jul 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  2. Jan 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

    First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Henning Bundgaard
Data source: Rigshospitalet, Denmark

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations